RxDoctor Payments Data

Mahmood Alnahass, MD

Neurology · Valparaiso, INNPI 1497756720

Payments from drug & device makers

$20,523in general payments, 2019–2025

Across 1,059 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AbbVie$2K
  • Biogen$1K
  • EMD Serono, Inc.$854
  • Teva Pharmaceuticals USA, Inc.$808
  • UCB, Inc.$790
  • plus $13K from 54 others

What the payments were for

  • Speaking & faculty fees$340%
  • Food & beverage$20,38699%
  • Education$1031%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis116$2,045
AbbVie(2 entities)136$2,034
Biogen63$1,081
EMD Serono, Inc.39$854
Teva Pharmaceuticals USA, Inc.61$808
UCB, Inc.43$790
Lilly USA, LLC38$743
Catalyst Pharmaceuticals, Inc.24$695
Amneal Pharmaceuticals LLC34$667
AstraZeneca(2 entities)20$611
SK Life Science, Inc.31$547
Johnson & Johnson22$546
Sanofi28$527
Lundbeck LLC25$514
Livanova USA, Inc.14$492
Eisai Inc.19$451
Banner Life Sciences, LLC22$450
MDD US Operations, LLC21$436
Acadia Pharmaceuticals Inc18$421
Pfizer20$388
Argenx US, Inc.19$368
Axsome Therapeutics, Inc.9$354
Bristol Myers Squibb18$330
Neurocrine Biosciences, Inc.15$328
Genentech USA, Inc.15$294
Kyowa Kirin, Inc.10$257
Supernus Pharmaceuticals, Inc.12$255
Adamas Pharmaceuticals, Inc.18$249
Jazz Pharmaceuticals Inc.11$219
Neurelis, Inc.7$219
Upsher-smith Laboratories LLC10$210
Acorda Therapeutics, Inc9$175
Biohaven Pharmaceuticals, Inc.9$168
E.r. Squibb & Sons, L.L.C.3$156
TG Therapeutics, Inc.8$150
Almatica Pharma LLC7$123
Otsuka America Pharmaceutical, Inc.7$121
Avanir Pharmaceuticals, Inc.7$118
Tanabe Pharma America, Inc.6$112
Scilex Pharmaceuticals Inc.5$107
Harmony Biosciences LLC3$99
Impel Pharmaceuticals Inc.6$99
Sunovion Pharmaceuticals Inc.5$89
Arbor Pharmaceuticals, Inc.7$87
Cycle Pharmaceuticals Inc3$68
Vanda Pharmaceuticals Inc.2$63
Biohaven Pharmaceutical Holding Company Ltd.3$57
Merz Pharmaceuticals, LLC2$50
OWP Pharmaceuticals, Inc.3$49
Abbott3$48
Corium, LLC3$44
Mallinckrodt Hospital Products Inc.2$39
Amgen2$39
Medtronic(2 entities)2$34
ANI Pharmaceuticals, Inc.2$31
Currax Pharmaceuticals LLC2$27
Philips North America LLC1$27
Ceribell, Inc.1$24
Assertio Therapeutics, Inc.1$21
Neuropace, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,523 in reported general payments places this provider in the 75th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$202,687
Medicare patients
636
Services billed
1,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm152$137,521
VumerityDiroximel Fumarate13$124,562
Avonex (4 Pack)Interferon Beta-1a14$115,556
UbrelvyUbrogepant68$76,804
Nurtec OdtRimegepant Sulfate54$66,604
FycompaPerampanel54$62,239
QuliptaAtogepant42$61,173
BotoxOnabotulinumtoxina38$57,968
BriviactBrivaracetam35$51,652
AptiomEslicarbazepine Acetate28$46,365
NourianzIstradefylline17$44,920
FingolimodFingolimod Hcl13$41,774
Lacosamide191$40,768
NeuproRotigotine31$34,352
Aimovig AutoinjectorErenumab-Aooe33$34,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity, Avonex (4 Pack)$1,081$240,11927 claims
AbbVieUbrelvy, Qulipta, Botox, Savella$2,034$203,932163 claims
UCB, Inc.Briviact, Neupro$790$86,00466 claims
PfizerNurtec Odt, Dilantin$388$72,91171 claims
Eisai Inc.Fycompa$451$62,23954 claims
Sunovion Pharmaceuticals Inc.Aptiom$89$46,36528 claims
Kyowa Kirin, Inc.Nourianz$257$44,92017 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$667$34,55469 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$255$26,15321 claims
Upsher-smith Laboratories LLCTopiramate$210$3,435192 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 308 neurology providers in Indiana.

Other neurology in Valparaiso

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →